Gapping up
News:
- IMMP +16.9% (receives US patent)
- DMTK +11.3% (receives positive medical benefit policy from Geisinger Health System)
- PLX +5.5% (Protalix BioTherapeutics and Chiesi Global rare diseases announce final results of BRIDGE Phase III open-label, switch-over clinical trial evaluating pegunigalsidase alfa for the treatment of fabry disease)
- TMDI +5% (provides regulatory update; FDA has indicated that, based on information provided to the agency, the Enos system is appropriate for classification through the De Novo pathway)
- GAN +4.1% (Dan Niles includes in his list of top picks for 2021 on CNBC)
- MRNA +2.9% (confirms discussions to supply 40 mln doses of COVID-19 vaccine to South Korea)
- HCM +2.2% (announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China for the treatment of non-pancreatic neuroendocrine tumors)
- EBS +2% (announces initiation of clinical program to evaluate COVID-HIG for prophylaxis)
- AZN +1.9% (AstraZeneca's COVID-19 vaccine authorized for emergency supply in the UK)
- JD +1.5% (authorized the Company to explore the feasibility and terms of a potential spin-off of the Company's JD Cloud & AI business to Jingdong Digits Technology Holding)
- MESA +1.3% (amends its Capacity Purchase Agreement with AAL)
- ODT +1.3% (Tang Capital Mgmt discloses 41.6% in amended 13D filing)
- BIP +1.2% (announced the appointment of David Krant as Chief Financial Officer of Brookfield Infrastructure, effective March 1, 2021)
- TSLA +1% (offers 3 months of free Full Self-Driving in unprecedented incentive, according to Electrek)
- MGA +1% (Dan Niles includes in his list of top picks for 2021 on CNBC)
Analyst comments:
- WIMI +4% (initiated with a Buy at The Benchmark Company)
- OPEN +3% (initiated with a Neutral at BTIG Research)
- DT +2.7% (initiated with a Buy at BTIG Research)